

Supplementary Table 1. Risk factors for candidemia, bacteremia and mortality among immunosuppressed patients with hematologic malignancies in multivariate analysis.

Incidence of invasive infections among hemato-oncology patients with significant burden of *Candida* in stool. *Mycopathologia*.

Ron Edri, Matan J Cohen, Danna Dror, Maya Korem

Corresponding author: Maya Korem, Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

mayak@hadassah.org.il

	Candidemia				Bacteremia				ESBL bacteremia				1-year mortality			
	Lower CI	Upper CI	OR	P value	Lower CI	Upper CI	OR	P value	Lower CI	Upper CI	OR	P value	Lower CI	Upper CI	OR	P value
Age	-0.024	0.021	0.99	0.88	-0.006	0.022	1	0.61	-0.02	0.013	1	0.43	0.007	0.038	1.02	0.02
Ethnicity																
Israeli	-0.174	1.569	1.8	0.11	-0.184	0.49	1	0.37	-0.744	0.349	0.8	0.48	-0.471	0.386	0.95	0.84
Non-Israeli	0.021	1.936	2.64	0.04	0.02	1.084	1.73	0.049	-0.834	0.303	0.71	0.24	-0.509	0.705	1.11	0.72
CSI	-1.938	0.728	0.6	0.48	-0.459	0.875	0.82	0.56	-1.142	0.537	1.52	0.31	-0.941	0.376	0.68	0.3
Profound neutropenia (ANC<100/ μ L)	0.195	3.462	5.82	0.03	-0.233	1.349	1.9	0.11	-0.016	2.381	3.3	0.053	-0.805	0.88	1	0.98
Severe (ANC<500/ μ L) and prolonged ($\geq$ 1 week) neutropenia	-0.573	1.612	1.74	0.31	0.264	1.614	2.43	0.01	-0.211	1.677	1.98	0.16	-0.707	0.751	1.21	0.6
HSCT ^a																
Allogeneic	-1.921	0.172	0.41	0.1	-0.36	0.885	1.32	0.37	-1.031	0.584	0.73	0.46	-0.45	0.957	1.27	0.51
Autologous	-3.221	0.216	0.21	0.07	-1.12	0.43	0.71	0.38	-1.66	0.422	0.65	0.44	-0.487	1.15	1.26	0.58
Corticosteroids ^{b,c}	-0.522	1.193	1.32	0.51	-0.111	0.887	1.47	0.12	-0.054	1.335	1.92	0.071	-0.677	0.414	0.88	0.66
Biologic treatment ^{b,d}	-2.801	0.476	0.31	0.17	-0.385	0.975	1.3	0.44	-0.233	1.529	2.06	0.1	-0.855	0.599	0.8	0.57
Systemic chemotherapy ^b	-1.773	0.849	0.62	0.48	-0.919	0.289	0.73	0.32	-0.836	0.805	1.09	0.829	-0.738	0.499	0.77	0.43
Anti-CD20 ^{e,f}	-3.669	0.647	0.21	0.16	-1.274	0.299	0.62	0.24					-1.041	0.526	0.78	0.54
Group (significant burden of stool <i>Candida</i> vs low burden or none)	-0.684	1.017	1.22	0.64	-0.828	0.277	0.74	0.29	-2.153	-0.371	0.3	0.009	0.053	1.215	2.01	0.02
Cause of diarrhea																
GVHD	-1.423	2.273	1.62	0.61	-0.594	1.548	1.61	0.38					-1.7	0.507	0.49	0.22
Infectious	-1.084	2.585	2.29	0.38	-0.643	1.447	1.48	0.45					-1.365	0.672	0.71	0.52
Unknown	-1.542	1.765	1.2	0.82	-0.375	1.445	1.68	0.26					-1.401	0.359	0.58	0.23
Previous antibiotics ^{b,g}																
Beta-lactam	0.042	2.686	4.01	0.04	0.044	1.215	1.85	0.03	-0.343	1.245	1.53	0.28	0.103	1.348	2.22	0.01
Carbapenem			1.1	0.87	0.087	1.642	2.36	0.03	-0.361	1.389	1.7	0.23	-1.515	0.43	0.59	0.3
Malignancy type	-1.281	0.985	0.93	0.9	-0.45	0.847	1.21	0.56	-1.192	0.732	0.75	0.55	-0.939	0.502	0.91	0.82
Bacteremia during hospitalization													-0.732	0.401	0.85	0.58
Candidemia during hospitalization													-3.391	-0.373	0.14	0.01

CSI; charlson severity index, ANC; absolute neutrophil count, HSCT; hematopoietic stem cell transplantation, GVHD; graft versus host disease

^aDuring hospitalization. ^bIn the previous 3 months prior to current hospitalization. ^c ≥ 0.3 mg/kg of prednisone (or equivalent) for ≥ 2 weeks. ^dMain agents were: BCR-ABL inhibitors imatinib, nilotinib, ponatinib; monoclonal antibodies brentuximab, daratumumab, blinatumomab; Bcl-2 inhibitor venetoclax; proteasome inhibitor bortezomib; Lenalidomide. ^eIn the past year. ^fRituximab, obinutuzumab. ^g ≥ 72 hours period of treatment.